Drug Profile
Fremanezumab - Teva Pharmaceutical Industries
Alternative Names: AJOVY; Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; fremanezumab-vfrm; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Rinat Neuroscience
- Developer Otsuka Pharmaceutical; Rinat Neuroscience; Teva Pharmaceutical Industries
- Class Analgesics; Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II Fibromyalgia; Headache; Interstitial cystitis
- Discontinued Cluster headache
Most Recent Events
- 11 Apr 2024 Efficacy and adverse events data from phase III clinical trials in Migraine released by Teva Pharmaceuticals
- 13 Mar 2024 Teva Pharmaceuticals completes the phase III SPACE trial for Migraine (In children, In adolescents, Prevention) in the US, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spainus (NCT04458857) (EudraCT2019-002055-42)
- 31 Dec 2023 Launched for Migraine (Prevention) in Australia (SC), by the end of 2023